Clinical trials: Affective Disorder
Treatment Resistant Depression
BPL-003 Efficacy and Safety in Treatment Resistant Depression
This is a Phase 2 study randomized, quadruple-masked, multi-center trial with an open-label extension (OLE), designed to investigate the efficacy and safety of BPL-003 in patients with treatment resistant depression (TRD).
- Trial name
- NCT05870540
- Testing
- BPL-003
- Where
- 42 sites in United States, Australia and 4 more
- Volunteers
- 196 people
- Sponsor
- Beckley Psytech Limited
Depression
Fevarin® Effectiveness in Treatment of Depression in Patients With Neurological Disorder
Prospective, multicenter, non-comparative, observational program to describe prevalence of depressive symptoms in a variety of neurological disorders and effects of Fevarin® on the severity of anxiety and depression, sleep state…
- Trial name
- FRIENDS (NCT02043197)
- Where
- 29 sites in Russia
- Volunteers
- 300 people
- Sponsor
- Abbott
Bipolar Disorder, Schizophrenia
Tachyphylaxis, Tolerance, & Withdrawal Post Treatment With Igalmi for Agitation in Schizophrenia or Bipolar Disorder
This is an in-clinic, single arm, open-label study assessing tachyphylaxis, tolerance, and withdrawal following repeated doses of Igalmi in adult males and females with agitation associated with schizophrenia or bipolar disorder.
- Conditions
- Bipolar Disorder, Schizophrenia, Agitation,Psychomotor, Schizo Affective Disorder
- Trial name
- NCT06041646
- Testing
- Sublingual film containing Igalmi
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- BioXcel Therapeutics Inc
Depressive Disorder, Major
Zelquistinel in the Treatment of Major Depressive Disorder
The purpose of this study is to evaluate the efficacy at 1 day post initial oral dose of zelquistinel (AGN-241751) compared with placebo in participants with Major Depressive Disorder (MDD).
- Trial name
- AGN-241751 (NCT03586427)
- Testing
- AGN-241751
- Where
- 25 sites in United States
- Volunteers
- 251 people
- Sponsor
- Syndeio Biosciences, Inc
Affective Psychosis, Bipolar, Bipolar Disorder
A Study to Evaluate the Efficacy and Safety of Adjustable Doses of Extended-release (ER) Paliperidone Compared With Placebo, in Combination With Lithium or Valproate, to Treat Manic and Mixed Episodes in Patients With Bipolar I Disorder
The purpose of this study is to evaluate the effectiveness and safety over a 6-week period of paliperidone ER compared with placebo in treating subjects with Bipolar I Disorder who are experiencing a manic or mixed episode while…
- Conditions
- Affective Psychosis, Bipolar, Bipolar Disorder, Mania
- Trial name
- NCT00309686
- Testing
- Paliperidone ER
- Volunteers
- 300 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Depressive Disorder, Major
Effectiveness Study of Vilazodone to Treat Depression and to Discover Genetic Markers Associated With Response
This study is designed to determine the safety and effectiveness of vilazodone for major depressive disorder and to discover genetic markers associated with response. This study will enroll approximately 400 patients.
- Trial name
- NCT00285376
- Testing
- vilazodone
- Where
- 15 sites in United States
- Volunteers
- 410 people
- Sponsor
- Genaissance Pharmaceuticals
Schizophrenia
A Study of the Effects of Paroxetine on the Pharmacokinetics of Paliperidone ER
The purpose of this study is to evaluate the effects of a CYP2D6 inhibitor, paroxetine, on the pharmacokinetics of a single dose of orally administered paliperidone ER and to evaluate the safety and tolerability of both…
- Trial name
- NCT00791713
- Testing
- Paliperidone ER
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Affective Psychosis, Bipolar, Mania
Non-interventional Study of Ziprasidone in the Treatment of Bipolar and Schizoaffective Disorders.
Assessment of ziprasidone safety and efficacy in the treatment of bipolar and schizoaffective disorders.
- Conditions
- Affective Psychosis, Bipolar, Mania, Manic-Depressive Psychosis
- Trial name
- NCT00454883
- Testing
- ziprasidone
- Volunteers
- 379 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Bipolar Depression
Lumateperone Monotherapy for the Treatment of Bipolar Depression Conducted Globally
The study will evaluate the efficacy and safety of ITI-007 in a randomized, double-blind, parallel-group, placebo-controlled, multi-center study in patients diagnosed with Bipolar I or Bipolar II disorder having a major…
- Trial name
- NCT03249376
- Testing
- Lumateperone
- Where
- 47 sites in United States, Bulgaria and 4 more
- Volunteers
- 381 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Schizophrenia, Bipolar Disorder
Research and Evaluation of Antipsychotic Treatment in Community Behavioral Health Organizations
The purpose of this study is to build a data repository that can be used to understand pharmaceutical utilization patterns among patients being treated in community behavioral health organizations (CBHOs) for schizophrenia or…
- Trial name
- NCT01181960
- Testing
- Risperidone long acting injectable - New Starts, Risperidone long acting injectable - Continuous Users, Paliperidone Palmitate -New and Continuous Users
- Where
- 34 sites in United States
- Volunteers
- 1,066 people
- Sponsor
- Janssen Scientific Affairs, LLC
Healthy Male
Determining Highest Dose Administration of TC-5214 and Evaluating Effect on the Electrical Activity in the Heart
This is a two part study. Part A will determine the maximum tolerated dose of TC-5214 administered to healthy male subjects in single ascending oral doses.
- Trial name
- NCT01359618
- Testing
- TC-5214, Moxifloxacin
- Where
- United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Depressive Disorder
Seasonal Affective Depression (SAD) Study
A placebo controlled study evaluating the effectiveness of medication in preventing winter depressive episodes in patients with a history of Seasonal Affective Disorder
- Trial name
- NCT00069459
- Testing
- Extended-release Bupropion Hydrochloride
- Where
- 48 sites in United States
- Volunteers
- 250 people
- Sponsor
- GlaxoSmithKline
Major Depressive Disorder
Comparison of Vortioxetine and Desvenlafaxine in Adult Patients Suffering From Depression
The purpose of this study is to compare the efficacy of vortioxetine versus desvenlafaxine after 8 weeks of treatment in patients that have tried one available treatment without getting the full benefit
- Trial name
- VIVRE (NCT04448431)
- Testing
- Vortioxetine, Desvenlafaxine
- Where
- 80 sites in Argentina, Belgium and 10 more
- Volunteers
- 605 people
- Sponsor
- H. Lundbeck A/S
Opioid Use Disorder
Virtual Reality Cognitive-Affective Training for Opioid Use Disorder- A Phase 2 RCT
The goal of this clinical trial is to examine the usefulness of a virtual reality-delivered intervention for individuals with opioid use disorder who are taking medication.
- Trial name
- NCT06021431
- Testing
- MORE-VR, Treatment as Usual
- Where
- 2 sites in United States
- Volunteers
- 128 people
- Sponsor
- BehaVR LLC
Depressive Disorder
MDD POC Study GSK372475 Subjects Depressive Disease
To evaluate the efficacy, safety and tolerability of GSK372475 compared with placebo in the treatment of outpatients subjects with major depressive disorder to exhibit decreased pleasure, interest and energy.
- Trial name
- NCT00420641
- Testing
- GSK372475, Paroxetine
- Where
- 33 sites in Bulgaria, Canada and 8 more
- Volunteers
- 492 people
- Sponsor
- GlaxoSmithKline
Depressive Disorder, Major Depressive Disorder
Study Evaluating Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR) In The Treatment Of Child and Adolescent Outpatients With Major Depressive Disorder
The primary purpose of this study is to evaluate the long-term safety and tolerability of Desvenlafaxine Succinate Sustained-Release (DVS SR) in child and adolescent outpatients with major depressive disorder.
- Trial name
- NCT00669110
- Testing
- Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR)
- Where
- 9 sites in United States
- Volunteers
- 40 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Major Depressive Disorder
AV-101 as Adjunct Antidepressant Therapy in Patients With Major Depression
The study will evaluate the safety and efficacy of AV-101.
- Trial name
- ELEVATE (NCT03078322)
- Testing
- AV-101
- Where
- 22 sites in United States
- Volunteers
- 180 people
- Sponsor
- VistaGen Therapeutics, Inc.
Major Depressive Disorder
Multiple Ascending Dose and Electroencephalography Trial of GATE-202 in Healthy Volunteers
To evaluate the safety, tolerability, pharmacokinetics and EEG pharmacodynamics of single and multiple ascending doses of apimostinel in normal human volunteers
- Trial name
- NCT05597241
- Testing
- apimostinel
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Syndeio Biosciences, Inc
Postpartum Depression
Pivotal Test: WB001
The purpose of the present randomized controlled study is to investigate if there is a difference in postpartum depression symptoms among participants assigned to : 1.
- Trial name
- NCT04576754
- Testing
- WB001, Educational
- Where
- United States
- Volunteers
- 83 people
- Sponsor
- Woebot Health
Healthy
Study Evaluating the Pharmacokinetics of Venlafaxine ER and Desvenlafaxine SR in Healthy Subjects
The purpose of this study is to determine if the relative difference in PK between extensive metabolizers (EMs) and poor metabolizers (PMs) is the same with desvenlafaxine SR and venlafaxine ER when a single dose is administered.
- Trial name
- NCT00329186
- Testing
- desvenlafaxine SR, venlafaxine ER
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.